Her New Job Paid $9,000 More. Its Plan Excluded Her GLP-1

The first sign was a line on the new insurance portal.

“Weight-loss medications: not covered.”

Marisol, the name used for this composite, saved a screenshot on her phone. She had accepted a new administrative job in Nevada that paid about $9,000 more a year, enough to ease the monthly squeeze for a single mother raising two children. The health plan also took less from each paycheck than her previous employer’s plan.

Then the pharmacy ran her first refill under the new coverage. The price was $1,349 for roughly one month.

That number changed the job calculation. Her raise amounted to about $750 a month before taxes, while the medication’s cash price was nearly twice that. She had paid $40 a month under her old plan and had taken the GLP-1 for 11 months under the care of her specialist.

The pharmacy price was not a medical bill she could negotiate after the fact. It was the price of getting the medication now. If she could not pay it, the pharmacy would return it to stock.

She opened the screenshot again. The portal did not say that the plan needed more records, that the medication required prior authorization or that she had to try something cheaper first. It said the category was not covered.

That distinction was the whole case.

The denial was hiding an exclusion

Insurance language tends to flatten different problems into the same word: denied. But a prior authorization denial and a benefit exclusion are not the same problem, even if both leave a person standing at a pharmacy without the medication.

A prior authorization denial means the plan covers a treatment under stated conditions but has decided, at least initially, that the patient has not shown those conditions were met. Records, previous treatments or a clinician’s explanation may change that decision.

An exclusion means the employer or insurer did not include that benefit in the plan. There may be no medical test to pass because the plan is refusing the category, not disputing the patient’s need within a covered category. An appeal can force the plan to explain and apply its own terms correctly. It generally cannot make an employer buy a benefit that the plan document leaves out.

That is what “not covered” was hiding on Marisol’s screenshot.

Coverage for GLP-1 medications can also depend on why a medication is prescribed. A plan may cover a drug for one condition while excluding it when prescribed for obesity. Marisol did not have the other condition associated with some GLP-1 products, and her specialist would not submit an inaccurate diagnosis to make the claim go through. That route was closed, as it should have been.

The exclusion was not unusual. In a 2024 survey from KFF, 18% of employers with at least 200 workers that offered health benefits said they covered GLP-1 drugs when used mainly for weight loss. Coverage was more common among the largest employers, but it was far from standard. Prescription coverage on an insurance card does not mean every prescription drug, or every use of a drug, is included.

None of that made $1,349 appear in Marisol’s checking account.

What the appeal could settle

She called the number on the back of the insurance card and asked whether the rejection was based on missing authorization or an exclusion. The representative confirmed that medications used for weight loss were excluded under her employer’s plan.

Marisol requested the denial in writing and the plan materials describing the exclusion. Her specialist’s office still submitted a coverage request explaining that she had been stable on the medication and asking the plan to continue it. The request was denied. The office then helped with an internal appeal.

The appeal mattered, though not in the way she first hoped. It created a written answer and made the plan state that it was applying a categorical exclusion, rather than claiming she had failed a medical rule that nobody had explained. It also ruled out weeks of repeatedly sending the same chart notes to people who had no authority to add the benefit.

There was a harder piece of bureaucracy underneath. Marisol’s employer funded its own health plan and hired an insurance company to administer it. The company whose name appeared on the card processed claims, but the employer had chosen the covered benefits. Self-funded employer plans are generally governed by federal law, while fully insured plans are also regulated by the state where the policy is issued.

Nevada’s insurance regulator could explain where a complaint belonged, but it could not rewrite a self-funded employer’s exclusions.

That arrangement is easy to miss. The insurance company says the employer chose the benefit. Human resources says the insurance company handles claims. The patient is left carrying a screenshot and a pharmacy price larger than her rent.

An external review was not a promising next step in her case. External review is designed for certain disputes involving medical judgment, rescissions and related coverage decisions. Marisol’s denial rested on a plain plan exclusion. The plan was not arguing that the GLP-1 was medically unnecessary; it was saying obesity medication was not a benefit it had agreed to pay for.

After five weeks, the internal appeal upheld the denial. Marisol added that letter to the screenshot on her phone. She did not pursue another review because the written decision made clear that the same exclusion would remain in place.

The three prices she compared

Her specialist discussed other treatments that were included on the plan’s drug list. This was not a swap between identical products. The covered medication worked differently, had its own risks and required a separate clinical decision, so the specialist reviewed Marisol’s history rather than treating the insurer’s cheaper option as automatically interchangeable.

The covered alternative would cost her $24 a month. Continuing the GLP-1 without insurance was quoted at $1,349. Going without prescription treatment would cost nothing at the pharmacy, but Marisol did not consider that a neutral financial choice after 11 months of care.

She checked whether a manufacturer program would reduce the GLP-1 price. The available terms could change, depended on insurance status and still left uncertainty she could not build a household budget around. Even a substantial temporary discount would not answer what happened when the offer ended.

The public numbers explained why her quote was so high but did not make it manageable. In 2024, the manufacturer’s list price for one widely prescribed GLP-1 approved for obesity was about $1,349 for a 28-day supply, before rebates or discounts. Insurers and benefit managers may pay different net prices. An uninsured patient at a pharmacy does not get to spend the confidential rebate that may exist elsewhere in the system.

Marisol considered using a health care flexible spending account when the next enrollment period arrived, but that would only let her use pretax money for an eligible expense. It would not turn a yearly drug cost above $16,000 into coverage. The money would still come from her pay.

The screenshot stayed on her phone because she kept returning to the same arithmetic: $9,000 more in annual salary, before taxes, against more than $16,000 in annual cash medication costs. A job advertised as a financial step forward could not absorb that subtraction.

What worked in her case

Marisol chose to try the covered alternative after discussing it with her specialist. Her first out-of-pocket charge was $24, and the office arranged follow-up rather than pretending the insurance decision had settled the medical one. She also sent a short benefits complaint to her employer without including detailed medical records, asking that obesity medications be considered during the next plan review.

The employer did not add GLP-1 coverage during that plan year. She never got the clean reversal people imagine when they hear the word appeal.

What worked was narrower. The appeal identified the barrier as a plan exclusion, which stopped her from spending months chasing authorization paperwork that could not fix it, and the covered medication gave her a treatment she and her specialist considered workable at a cost her budget could hold. Six months later, she was still taking it and paying $24.

She kept the screenshot. Beneath the exclusion line, the portal still displayed the new plan as active.

Questions people ask

Can

I appeal when a new employer plan excludes my GLP-1?

Marisol could appeal, and her specialist did. The appeal produced a written decision confirming that the drug category was excluded, but it did not add a benefit the employer had left out. Her most useful first distinction was whether the rejection involved medical criteria, missing authorization or a categorical exclusion.

Does a plan have to keep covering a medication my old plan covered?

Changing employer plans can change the drug list, authorization rules and exclusions. Marisol’s 11 months of prior coverage did not bind the new plan. Her specialist requested continuity, but the new plan applied its obesity-drug exclusion rather than continuing the old insurer’s decision.

Can an external review overturn a weight-loss drug exclusion?

External review may address certain denials involving medical judgment or related coverage disputes, but Marisol’s case rested on an explicit benefit exclusion. Her written appeal decision said the plan was not evaluating whether the drug was medically necessary; it was declining to cover that category under the employer’s benefit design.

What did she do when the cash price was unaffordable?

Marisol compared the $1,349 pharmacy quote with a covered treatment discussed by her specialist. She chose the covered option, arranged follow-up and asked her employer to reconsider obesity-drug coverage in a future plan year. Her next pharmacy receipt showed $24.